Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC).

Expert opinion on pharmacotherapy - 1 Aug 2022

Byun Joo-Young, Park Sun-Kyeong, Ng Boon Peng, Liu Yi-Shao, Kim Chae-Rin, Park Chanhyun

Abstract excerpt

INTRODUCTION: Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to high costs. Despite the critical role of the cost-effectiveness of TKIs on decision-making, no systematic reviews have compared the cost-effectiveness of comparable TKIs. Therefore, we systemically reviewed the economic evaluation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 35759783
DOI: 10.1080/14656566.2022.2095203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC).PMID 35759783Read ↗

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read ↗

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity Read ↗

Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.Semantic proximity Read ↗

Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review.Semantic proximity Read ↗

Clinical and economic review of erlotinib in non-small-cell lung cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.Semantic proximity Read ↗

Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.Semantic proximity Read ↗

Cost-Utility Analysis of Adjuvant Osimertinib in Resected Epidermal-Growth-Factor-Receptor-Mutated Early-Stage Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.